Literature DB >> 25944943

Pharmacologic Agents That Promote Airway Clearance in Hospitalized Subjects: A Systematic Review.

Nila A Sathe1, Shanthi Krishnaswami2, Jeff Andrews2, Cathy Ficzere3, Melissa L McPheeters4.   

Abstract

Pharmacologic agents to promote mucus clearance may reduce the sequelae of obstructive secretions. We systematically reviewed comparative studies of pharmacologic agents for mucus clearance in hospitalized or postoperative subjects without cystic fibrosis and over 12 months of age. We searched MEDLINE and other databases from January 1970 to July 2014 to identify relevant literature. Two reviewers independently assessed each study against predetermined inclusion/exclusion criteria. Two reviewers also independently extracted data regarding subject and intervention characteristics and outcomes and assigned overall quality ratings. The 9 studies meeting review criteria included 5 randomized controlled trials, 3 crossover randomized controlled trials, and one retrospective cohort study. Studies were small and together included a total of 379 subjects (mean of 42 subjects per study). N-acetylcysteine, heparin plus N-acetylcysteine, albuterol, ipratropium bromide, and saline were assessed. Studies reported no benefit of studied agents on expectoration, pulmonary function, and atelectasis and little effect on changes in sputum volume, weight, or viscosity. Adverse effects of agents were not consistently reported. Nausea was reported in 2 studies of N-acetylcysteine (one paper reported 2 experiments and did not clearly identify in which experiment adverse effects occurred), 3 studies reported that there were no adverse events, and 3 studies did not address adverse effects at all. Further research with clearly characterized populations and interventions is needed to understand the potential benefits and adverse effects of mucoactive agents.
Copyright © 2015 by Daedalus Enterprises.

Entities:  

Keywords:  airway clearance; drug therapy; mucoactive agents; mucus clearance

Mesh:

Substances:

Year:  2015        PMID: 25944943     DOI: 10.4187/respcare.04086

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  5 in total

Review 1.  Short-acting inhaled bronchodilators for cystic fibrosis.

Authors:  Sherie Smith; Nicola J Rowbotham; Christopher T Edwards
Journal:  Cochrane Database Syst Rev       Date:  2022-06-24

2.  Use of nebulised N-acetylcysteine as a life-saving mucolytic in intensive care: A case report.

Authors:  Elizabeth A Brodier; Meera Raithatha; Santhana Kannan; Niroshini Karunasekara
Journal:  J Intensive Care Soc       Date:  2019-09-19

3.  Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial.

Authors:  Martin Koppitz; Charlotte Eschenburg; Emilia Salzmann; Martin Rosewich; Ralf Schubert; Stefan Zielen
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

4.  Assessment of the Efficacy and Safety of Ivy Leaf (Hedera helix) Cough Syrup Compared with Acetylcysteine in Adults and Children with Acute Bronchitis.

Authors:  Esther Kruttschnitt; Tankred Wegener; Catherine Zahner; Silke Henzen-Bücking
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-04       Impact factor: 2.629

Review 5.  Scientific Papers and Patents on Substances with Unproven Effects. Part 2.

Authors:  Sergei V Jargin
Journal:  Recent Pat Drug Deliv Formul       Date:  2019
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.